Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Upgraded by JPMorgan Chase & Co. to Overweight Rating

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) was upgraded by analysts at JPMorgan Chase & Co. from a “neutral” rating to an “overweight” rating in a research report issued on Monday, Marketbeat reports.

A number of other equities research analysts have also issued reports on BAYRY. Wall Street Zen upgraded shares of Bayer Aktiengesellschaft from a “buy” rating to a “strong-buy” rating in a report on Tuesday, August 19th. Morgan Stanley raised Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a report on Wednesday, December 3rd. Finally, Zacks Research lowered Bayer Aktiengesellschaft from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 3rd. Two analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Buy”.

Bayer Aktiengesellschaft Price Performance

BAYRY opened at $9.67 on Monday. Bayer Aktiengesellschaft has a twelve month low of $4.79 and a twelve month high of $10.03. The firm has a market cap of $38.00 billion, a price-to-earnings ratio of -107.43, a PEG ratio of 4.90 and a beta of 0.69. The company has a current ratio of 1.13, a quick ratio of 0.73 and a debt-to-equity ratio of 1.04. The company has a fifty day simple moving average of $8.21 and a 200 day simple moving average of $7.99.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.